Details

Autor(en) / Beteiligte

• Weatherald, Jason
• Chaumais, Marie-Camille
• Savale, Laurent
• Jaïs, Xavier
• Seferian, Andrei
• Canuet, Matthieu
• Bouvaist, Hélène
• Magro, Pascal
• Bergeron, Anne
• Guignabert, Christophe
• Sitbon, Olivier
• Simonneau, Gérald
• Humbert, Marc
• Montani, David

Titel

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study

Ist Teil von

• The European respiratory journal, 2017-07, Vol.50 (1), p.1700217-1700217

Ort / Verlag

England: European Respiratory Society Journals Ltd

Erscheinungsjahr

2017

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• This study aimed to describe the long-term outcomes of pulmonary arterial hypertension (PAH) induced by dasatinib.21 incident, right heart catheterisation-confirmed cases of dasatinib-induced PAH were identified from the French Pulmonary Hypertension Registry. Clinical and haemodynamic variables were compared from baseline to last follow-up (median (range) 24 (1-81) months).Median age was 52 years and 15 patients were female (71%). 19 patients received dasatinib for chronic myelogenous leukaemia for a median (range) duration of 42 (8-74) months before PAH diagnosis. No bone morphogenic protein receptor-2 ( ) mutations were found in the 10 patients tested. Dasatinib was uniformly discontinued and 11 patients received PAH medications. Four patients died during follow-up. New York Heart Association functional class improved from 76% in class III/IV to 90% in class I/II (p<0.01). Median (range) 6-min walk distance improved from 306 (0-660) to 430 (165-635) m (p<0.01). Median (range) mean pulmonary arterial pressure improved from 45 (30-70) to 26 (17-50) mmHg (p<0.01) and pulmonary vascular resistance from 6.1 (3.2-27.3) to 2.6 (1.2-5.9) Wood units (p<0.01). Patients treated with PAH medications had worse baseline haemodynamics but similar long-term outcomes to untreated patients. PAH persisted in 37% of patients.Dasatinib-induced PAH frequently improves after discontinuation but persisted in over one-third of patients, therefore systematic follow-up is essential.